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Abstract
Minimizing adverse reactions caused by drug-drug interactions has
always been a momentous research topic in clinical pharmacol-
ogy. Detecting all possible interactions through clinical studies
before a drug is released to the market is a demanding task. The
power of big data is opening up new approaches to discover various
drug-drug interactions. However, these discoveries contain a huge
amount of noise and provide knowledge bases far from complete
and trustworthy ones to be utilized. Most existing studies focus
on predicting binary drug-drug interactions between drug pairs but
ignore other interactions. In this paper, we propose a novel frame-
work, called PRD, to predict drug-drug interactions. The frame-
work uses the graph embedding that can overcome data incomplete-
ness and sparsity issues to achieve multiple DDI label prediction.
First, a large-scale drug knowledge graph is generated from differ-
ent sources. Then, the knowledge graph is embedded with com-
prehensive biomedical text into a common low dimensional space.
Finally, the learned embeddings are used to efficiently compute rich
DDI information through a link prediction process. To validate
the effectiveness of the proposed framework, extensive experiments
were conducted on real-world datasets. The results demonstrate
that our model outperforms several state-of-the-art baseline meth-
ods in terms of capability and accuracy.
1 Introduction
An increasing amount of research in clinical studies focuses
on drug-drug interactions (DDIs) because the majority of ad-
verse drug reactions (ADRs) occur between pairs of drugs.
ADRs may lead to patient morbidity and mortality, and they
account for 3-5% of all in-hospital medication errors [18].
To make matters worse, patients with two or more diseases,
e.g., elderly patients with chronic diseases, have a higher risk
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of an ADR if they take five or more different drugs simulta-
neously [14]. Detecting DDIs based on experimentation is
a time-consuming and laborious process for clinicians. This
signals the need for a more comprehensive and automated
method of predicting unknown DDIs before a drug is re-
leased.
Many existing methods, such as [29, 32, 1], leverage the
existing properties of the drugs and use similarity measure-
ments to predict DDIs. Independent similarity scores for a
candidate pair of drugs are computed and used as the input
for a machine learning classifier (e.g., a logistic regression
model), which outputs a binary prediction. However, DDI
predictions should not be as narrow as a simple true or false
question. The interactions between drugs in real-world data
resources exhibit rich and variant meanings (e.g., increasing
hematologic toxicity and high-risk infections). Capturing de-
tailed DDI information may help caregivers make more ac-
curate and safe medical prescriptions. Recently, Jin et al.
[13] proposed a multitask learning framework to detect mul-
tiple types of DDIs among developed drugs. Unfortunately,
this framework relies on adverse DDIs (e.g., heart rate in-
crease) that have been pre-defined in a structured database
and largely ignores pharmacological DDI information in un-
structured biomedical texts. As a result, this method is not
able to generate in-depth insights into the underlying mech-
anisms of DDIs. More critically, this multitask learning
framework suffers from sparsity issues and has limitations
on large-scale datasets because it employs a one-hot feature
vector and treats each drug as a unique symbol.
Motivation. Many biomedical knowledge bases are
published as knowledge graphs (KGs), as illustrated in Fig-
ure 1. In KGs, nodes are entities, which might include drugs,
diseases, protein targets, substructures, side effects, path-
ways, etc. The edges (or links) represent the various relations
between the nodes, such as drug-target interactions. Data
items in different knowledge bases can therefore be linked to
form large heterogeneous graphs, such as the Bio2RDF [2]
and the Linked Open Drug Data [26]. These heterogeneous
graphs provide an abundance of drug-related information to
determine whether a DDI exists between a drug combina-
tion. Furthermore, as shown in Figure 1, DDIs are frequently
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Figure 1: A drug knowledge graph is shown on the left
with missing relations represented as dotted lines. There
is usually no direct DDI relation between drugs. DDI
descriptions from biomedical texts are shown on the right.
The words colored red represent concerns regarding DDI
information in terms of both adverse DDIs and in-depth ways
drugs can interact in pharmacology.
described in unstructured biomedical texts, such as pharma-
cology literature or clinical reaction reports. Obviously, the
increasing emergence of biomedical texts offers an opportu-
nity to uncover more than multiple adverse reactions, such as
specific synergies or antagonistic effects in pharmacology.
Challenges. Leveraging both drug KGs and biomedical
texts is a promising pathway for rich and comprehensive DDI
prediction, but it is not without issues. Our model confronts
the following challenges: 1. Data Noise and Incompleteness.
Real-world KGs are known to be inaccurate, incomplete, and
unreliable for direct use. 2. Data Sparsity. The potential
DDI information in both KGs and biomedical texts is sparse.
It is a tough task to estimate potential DDIs in such long-
tail distribution. 3. Computational Efficiency. Undoubtedly,
computational complexity will be precluded from practice if
graph-based algorithms are employed to process large-scale
KGs or represent data objects with simple one-hot feature
vectors.
Solution. Given these challenges, we propose a novel
framework called PRD. The framework is based on graph
embedding techniques and treats specific DDI predictions
as a linked prediction process. The procedure includes the
following:
1. A large, high-quality drug KG is generated from dis-
tributed drug resources, including drug-target interac-
tions, the impact of drugs on gene expression, the out-
comes of drugs in clinical trials, and so on.
2. A novel translation-based embedding model embeds
the entities and relations in the drug KG into a low-
dimensional space. And an autoencoder incorporates
the descriptions of the DDIs from biomedical texts as
representations into the same semantic space.
3. The decoder predicts the corresponding labels for po-
tential DDIs based on the learned embeddings.
Contributions. In summary, our method PRD makes
the following contributions.
1. To the best of our knowledge, this is the first method
that is able to predict comprehensive and specific DDIs
based on a large-scale drug KGs and comprehensive
biomedical texts from pharmacology to ADRs.
2. The method includes a joint translation-based embed-
ding model that encodes the KG and rich DDI in-
formation from biomedical texts into a common low-
dimensional space. Then, the DDI predictions are trans-
lated into a linked prediction process from the learned
embeddings.
3. Extensive experiments on real-world datasets were con-
ducted to evaluate the framework. The results show
that the framework can be powerful in predicting rich
DDIs and outperforms several state-of-the-art baselines
in terms of both capability and accuracy.
The remainder of the paper is organized as follows.
Related work is discussed in Section 2. Section 3 presents
the details of the proposed framework. The evaluation of the
framework is reported in Section 4. Finally, our conclusions
and future work are presented in Section 5.
2 Related Work
This section discusses existing related research, including
DDI detection, biomedical KGs, and graph embedding.
DDI detection is a major issue in pharmacological re-
search. Traditional experimental approaches in vitro [11], in
vivo [23], and in populo [27] focus on small sets of specific
drug pairs and have laboratory limitations. As mentioned in
Section 1, many computational approaches have been pro-
posed to predict DDIs in recent years. However, similarity
or feature-based approaches [29, 32, 1, 13] only predict bi-
nary DDIs or those that have been pre-defined in structured
databases and suffer from robustness caused by data sparsity
and vast computation requirements. Although several ap-
proaches [10, 4, 20] have used natural language processing
techniques to extract DDIs from biomedical texts, to the best
of our knowledge, they have not employed drug knowledge
graphs to improve performance.
With the increasing emergence of biomedical data,
many world-leading biomedical researchers are now focus-
ing on automatically populating and completing biomedical
KGs using the huge volume of structured databases and texts
available to the public. HKG [25], Knowlife [6] and Drug-
Bank [17] are just a few examples. Efforts such as Bio2RDF
[2] and Linked Open Drug Data [26] have mapped simi-
lar entities in different KGs and built large heterogeneous
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graphs that contain an abundance of basic biomedical facts
about drugs. SPARQL [7], a query language for KGs, sup-
ports the retrieval and manipulation of drug-related facts dis-
tributed over different KGs. Unfortunately, these biomedical
KGs are affected by incomplete and inaccurate data that im-
pede their application in the field of safe medicine develop-
ment.
Existing KGs already include thousands of relation
types, millions of entities and billions of facts [26]. As
noted, KG applications based on conventional graph-based
algorithms are compromised by data sparsity and computa-
tional inefficiency. To address these problems, graph em-
bedding techniques [3, 31, 19, 24] based on representation
learning for KGs have been proposed to embed both en-
tities and relations into a continuous low-dimensional vec-
tor space. Among these methods, translation-based models
[3, 31, 19] are the most simple and effective. Currently, they
represent state-of-the-art performance for knowledge acqui-
sition and inference as well as link prediction [3]. Inspired
by these analogies, DDI can be treated as a category of rela-
tions in a drug KG, and KG embedding techniques could be
used to predict unknown DDIs. However, most translation-
based methods only concentrate on pre-defined relations be-
tween entities, ignoring the rich relation information in un-
structured texts.
3 The Proposed Framework
Figure 2 shows the architecture of the proposed framework.
It consists of three key phases: drug KG generation (de-
scribed in 3.1), jointly embedding learning (described in 3.2)
and DDI prediction (described in 3.3).
3.1 Drug KG Generation A typical KG usually arranges
knowledge as a triple set of facts that indicate the relation
between two entities., i.e., a head entity, a relation, and a tail
entity. These are denoted as (h, r, t).
First, a basic drug KG is constructed by collecting drug-
related entities and relations among these entities. Accord-
ing to the underlying mechanisms that govern the interac-
tions between two drugs [12], SPARQL federation queries
[7] are adopted to extract triples that contain four types of
drug-related entities (E1 ∼ E4) and five types of biolog-
ical relations (R1 ∼ R5 ) from a variety of biomedical
sources (Bio2RDF [2]). Table 1 summaries the types of en-
tities/relations in detail1. These extracted triples are defined
as basic triples in our drug KG:
Definition 1. (BASIC TRIPLE) B = (E,R) is a set of basic
triples in the form (h, r, t), where E = E1 ∪ E2 · · · ∪ E4 is
1In this paper, “proteins” is used generically to represent different
biomedical concepts, such as “genes,” “enzymes,” and “transporters.” Sim-
ilarly, “phenotype” represents diseases and adverse drug reactions.
Table 1: Entities and relations of basic triples in drug KG.
Variable Entity/Relation Interpretation
E1 ∼ E5 E1: drugs, E2: proteins,E3: pathways, E4: phenotypes.
R1 ∼ R5
R1: (drug, hasTarget, protein)
R2: (drug, hasEnzyme, protein)
R3: (drug, hasTransporter, protein)
R4: (protein, isPresentIn, pathway)
R5: (pathway, isImplicatedIn, phenotype).
a set of entities, R = R1 ∪ R2 · · · ∪ R5 is a set of relations,
h, t ∈ E, and r ∈ R.
For instance, (Lepirudin, hasTarget, prothrombin) is
a basic triple in our drug KG and indicates that there is a
relationship hasTarget, linking Lepirudin to prothrombin.
A specific DDI between two drugs can be captured
by multiple key phrases extracted from biomedical texts,
as shown in Figure 1. Hence, we collect biomedical DDI
texts documenting drug pairs (e.g., DDI corpus [8], MedLine
abstracts2, and DrugBank DDI documents). We remove all
stop words from raw texts and use an entity linking method
[30] to align the drug names in the biomedical texts with the
KG. Then, the top-n labels3 are selected from the biomedical
texts for each DDI based on TF-IDF features (some other
textual features can be used to rank the labels instead). Based
on this, the DDI relations between drug entities are defined
as a set of labels, rather than as a single label.
Definition 2. (RICH DDI TRIPLE) T = (E1, L) is a set of
rich DDI triples in the form (u, l, v), where E1 is a set of
drug entities, L is a fixed label vocabulary from biomedical
text, u, v ∈ E1, and l = {n1, n2, ...} ⊆ L is the set of labels
to describe the DDI information.
For instance, (Etanercept, {immunosuppressants,
enhancetoxicity, anemia, infections}, Leflunomide)
is a rich DDI triple. Note that the DDI relations between two
drugs are bidirectional; hence, our method represents each
DDI relation with two directed triples in opposite directions
in the drug KG.
Formally, the generated drug knowledge graph is de-
fined as follows.
Definition 3. (DRUG KNOWLEDGE GRAPH) The drug
knowledge graph G is denoted as (E,B, T ), where
E = E1 ∪E2 · · · ∪E4 is a set of entities, B is a set of basic
triples and T is a set of rich DDI triples.
3.2 Model Description This section introduces the
translation-based embedding model that learns representa-
2https://www.medline.com/
3We set n=5 in this paper.
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Figure 2: Overview of the framework.
tions from the drug knowledge graph G = (E,B, T ) and
the optimization method as follows.
3.2.1 Basic Triple Encoder (BTE) For a set of basic
triples B, the method aims to encode entities and relations
into a continuous vector space. This paper, without loss
of generality, uses the bold letters h, r, t to denote the
embedding vectors h, r, t. We adopt the translation-based
mechanism h + r ≈ t to capture the correlations between
entities and relations. Translation in this context refers to a
translation operation r between two entity vectors h and t
in the low-dimensional space. We follow the TransR model
in [19] to represent entities and relations in distinct vector
spaces bridged by relation-specific matrices so as to learn
more thorough graph representations. Specifically, for each
triple (h, r, t) ∈ B, h and t are embedded into h, t ∈ Rk, and
r is embedded into r ∈ Rd. For each relation r, a projection
matrix Mr ∈ Rk×d projects entities from the entity space to
the relation space. Then, the energy function zbte(h, r, t) is
defined as:
(3.1) zbte(h, r, t) = b1 − ‖hMr + r− tMr‖L1/L2
where b1 is a bias constant.
The conditional probability of a triple (h, r, t) is defined
as follows:
(3.2) P (h|r, t) = exp{zbte(h, r, t)}∑
hˆ∈E exp{zbte(hˆ, r, t)}
P (t|h, r), P (r|h, t) can be defined in an analogous manner.
The likelihood of observing a triple (h, r, t) is defined as:
L(h, r, t) = logP (h|r, t) + logP (t|h, r)
+ logP (r|h, t)(3.3)
By maximizing the conditional likelihoods of all exist-
ing triples in B, the objective function is defined as follows:
(3.4) Lbte =
∑
(h,r,t)∈B
L(h, r, t)
It is worth mentioning that other graph embedding mod-
els, such as HOLE [22] and RDF2vec[24], can also be easily
adopted for basic triple encoding. Due to the space limit, in
this paper we only explore the effectiveness of TransR.
3.2.2 Rich DDI Triple Encoder (RDTE) The interaction
l between two drug entities u, v in rich DDI triples (u, l, v) ∈
T can also be represented as translations in low-dimensional
space. We set u,v ∈ Rk, l ∈ Rd. The energy function
zdte(u, l, v) is defined as:
(3.5) zdte(u, l,v) = b2 − ‖uMl + l− vMl‖L1/L2
where b2 is a bias constant and Ml ∈ Rk×d is the projection
matrix. Following the analogous method in BTE, the con-
ditional likelihoods of all existing triples are maximized as
follows:
(3.6) Ldte =
∑
(u,l,v)∈T
L(u, l, v)
Note, in Eq.(3.5), l is the relation representation ob-
tained from l = {n1, n2, ...}. This is demonstrated in-depth
next.
A deep autoencoder is employed to construct the rela-
tion representation l ∈ Rd for a rich DDI triple (u, l, v) ∈ T .
Specifically, a DDI relation l is described by a set of labels
l = {n1, n2, ...} ⊆ L. The corresponding binary vector for
l is initialized as s = {si}|L|i=1, where si = 1 if ni ∈ l,
and si = 0 otherwise. The deep autoencoder then takes the
binary vector s as input and uses the following non-linear
Copyright c© 2018 by SIAM
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transformation layers to transform the label set into the low-
dimensional space Rk:
(3.7)
h(1) = f(W(1)s+ b(1)),
h(i) = f(W(i)hi−1 + b(i)), i = 2, ...,K.
where f is the activation function and K is the number of
layers. Here, h(i),W(i) and b(i) represent the hidden vector,
transformation matrix and the bias vector in the i-th layer
respectively.
There are two parts to the autoencoder: an encoder and
a decoder. The encoder employs the tanh activation func-
tion to obtain the DDI relation representation l = h(K/2).
The decoder deciphers the embedding vector of l to obtain
a reconstructed vector s˜. Intuitively, PRD should then min-
imize the distance ‖s − s˜‖L1/L2 because the reconstructed
vector s˜ should be similar to s. However, the number of
zero elements in s is usually much larger than non-zero el-
ements due to data sparsity. This leads the decoder tends
to reconstruct zero elements rather than non-zero elements,
which conflicts with our purpose. To overcome this obsta-
cle, different weights are set for different elements, and the
following objective function is maximized:
(3.8) zl(s, s˜) = b3 − ‖(s− s˜) x‖L1/L2
where b3 is a bias constant, x is a weight vector and  is
denoted as the Hadamard product. For x = {xi}|L|i=1, xi = 1
if si = 0, and xi = β > 1 otherwise. According to Eq.(3.8),
the probability of P (s|s˜) can be defined as follows:
(3.9) P (s|s˜) = exp{zl(s, s˜)}∑
sˆ∈S exp{zl(ˆs, s˜)}
where S is the set of binary vectors of all DDI relations. The
likelihood of reconstructing the binary vector s of a relation
l can be defined as:
(3.10) L(l) = logP (s|s˜)
By maximizing the likelihoods of the encoding and the
decoding for all described relations l, the objective function
can be defined as follows:
(3.11) Lrcl =
∑
l∈T
L(l)
3.2.3 Joint Learning and Optimization The goal of the
framework PRD is to not only represent the basic triples
(drug KG B) but also rich DDI triples (biomedical text T )
in a unified joint embedding model. Considering the above
three objective functions Eq.(3.4) (3.6) (3.11) together, the
optimization function is defined as:
(3.12) O(X) = Lbte + Ldte + Lrcl + γC(X)
whereX represents the embeddings of entities and relations,
and γ is a hyper-parameter that weights the regularization
factor C(X), which is defined as follows:
C(X) =
∑
e∈E
[||e|| − 1]+ +
∑
r∈R
[||r|| − 1]+
+
∑
l∈L
[||l|| − 1]+
(3.13)
where [x]+ = max(0, x) denotes the positive part of x.
The regularization factor will normalize the embeddings
during learning. We adopt the approach in [28] to prevent
deep neural networks from overfitting, and use the Adam
algorithm [16] to maximize the objective function.
It is impractical to directly compute the normalizers in
P (h|r, t), P (t|h, r), P (r|h, t) and P (s|s˜), as calculating
them would require summing the complete set of entities
and relations. To address this problem, we use the nega-
tive sampling method from [21] to transform the objective
functions. Taking P (h|r, t) as an example, the following ob-
jective function is maximized instead of using its original
form:
log σ(zbte(h, r, t))
+
c∑
m=1
Eh˜m∼zneg({(h˜,r,t)})[σ(zbte(h˜m, r, t))]
(3.14)
where c is the number of negative examples, σ(x) = 1/(1 +
exp(−x)) is the sigmoid function, {(h˜, r, t)} is the invalid
triple set, and zneg is a function randomly sampling instances
from {(h˜, r, t)}. When a positive triple (h, r, t) ∈ B
is selected to maximize Eq.(3.14), c negative triples are
constructed by sampling entities from a uniform distribution
over E and replacing the head of (h, r, t). The objective
functions of P (r|h, t), P (t|h, r), logP (s|s˜) and L(u, l, v)
are transformed and maximized in an equivalent manner.
Finally, PRD iteratively selects random mini-batches from
the training set to learn the embeddings efficiently until
convergence.
3.3 Predicting DDI Relations With the learned deep au-
toencoder and the embedding vectors of all entities and re-
lations, the framework PRD can now leverage the transla-
tion mechanism to predict the DDI relations between two
drug entities. To be more specific, given two drugs entities
u, v ∈ E1, the following equation predicts the potential rela-
tion embedding l between u and v.
(3.15) l = vMl − uMl
Finally, with the decoder part of the learned deep au-
toencoder, PRD can obtain the label set l by decoding the
embedding vector l.
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4 Experiments and Evaluation
To scrutinize the effectiveness of the DDI prediction frame-
work PRD, we performed two types of experiments. First,
we compared the performance of our model to several base-
line methods on binary-type DDI predictions. Then we in-
vestigated PRDs strengths in modeling rich DDI relations
between drug entities. The results demonstrate that PRD sig-
nificantly outperformed the baselines in terms of both accu-
racy and capability.
4.1 Dataset Construction Experiments in this paper were
performed on two real drug-related datasets, Bio2RDF [2]
and DDI Corpus [8].
• Bio2RDF (version 4) is an open-source project that pro-
vides 11 billion triples from 35 biological and pharma-
cological KGs across a wide variety of drug-related en-
tities, such as proteins, targets, and diseases. It is acces-
sible on the Web via the SPARQL endpoint4.
• DDI Corpus (2013 version) is a semantically annotated
corpus of documents describing DDIs from the Drug-
Bank database and MedLine abstracts. It contains 233
MedLine abstracts and 784 DrugBank texts on the DDIs
subjects. There are a total of 5,021 annotated DDIs in
18,491 pharmacological sentences.
We used SPARQL federation queries to extract basic
triples for our drug KG from four different KGs in Bio2RDF:
1) DrugBank [17] provides comprehensive data about drug,
disease and target information. 2) Kyoto Encyclopedia of
Genes and Genomes (KEGG) [15] offers biological data of
pathways, proteins, and drugs. 3) PharmGKB [9] renders
us protein-drug-disease-relations. 4) Comparative Toxicoge-
nomics Database (CTD) [5] furnishes data about protein in-
teractions and pathway-disease relations.
For the rich DDI triples, we collected the 4,694 Drug-
Bank DDI sentences about 8,197 drugs from DDI corpus.
Top-5 labels from each sentence were selected based on TF-
IDF to construct rich DDI triples and build the DDI label
vocabulary. Since we undergo the issue on inconsistent drug
names between basic triples and rich DDI triples, we apply
the entity linking method [30] to align the drug aliases.
The details of the drug KG we constructed are shown in
Table 2.
4.2 Baselines The following three DDI prediction ap-
proaches and two state-of-the-art KG embedding methods
were employed as baselines:
• Tiresias [1] is a large-scale similarity-based framework
that predicts DDIs through link prediction. It takes
4http://bio2rdf.org/
Table 2: Statistics of the generated drug KG
#Basic triples 71,460 #Drug entities 8,197
#Rich DDI triples 4,694 #Other entities 305,642
#Distinct labels in the DDI vocabulary 1,053
various sources of drug-related data and knowledge as
inputs, and generates binary DDI predictions as outputs.
• SCNN [33] represents a DDI extraction method based
on a syntax convolutional neural network to extract four
pre-defined DDI types (ADVICE, EFFECT, INT and
MECHANISM) from the biomedical literature.
• Multitask dyadic DDI prediction (MDDP) [13] defines
the DDI type prediction problem as a multitask dyadic
regression problem. It can predict the specific DDI type
between two drugs.
• TransE [3] is the most representative translational dis-
tance model to embed components of a KG, includ-
ing entities and relations, into continuous vector spaces.
Those embeddings can also be used for link prediction.
• TransR [19] shares a similar approach with TransE, but
represents entities and relations in distinct vector spaces
bridged by relation-specific matrices.
4.3 Evaluation Method and Metrics Given a drug KG
with some DDI relations removed, rich DDI prediction aims
to predict the occurrence of DDI relations among drug
entities. Thirty percent of DDI relations, chosen randomly
as the ground truths for the test set, were removed and the
remaining KG was used the training set. We also randomly
sampled an equal number of drug pairs with no DDI relations
to serve as the negative sample in the test set.
To make an unbiased comparison, we first treated DDI
prediction as a binary classification task. Tiresias is already
a binary classification model. For SCNN and MDDP, we de-
fined the two DDI types as yes and no in the training model.
For TransE, TransR and our method PRD, we concatenated
the representations of the entities of a candidate drug pair to
form the feature vector and used logistic regression to train
classifiers. We then treated multiple DDI type predictions as
a multi-label classification task. For Tiresias, SCNN, and
MDDP, we used their feature representation methods and
adopted one-vs-rest logistic regression to train a multi-label
classifier. For TransE and TransR, we separated each training
triple (u, l, v), where l = {n1, n2, ...}, into several triples,
i.e., (u, ni, v) for ni ∈ l, which can be directly used to train
the models.
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Table 3: Evaluation results for multiple DDI relation predictions.(×100 for Hits@k)
Metric Raw Filter
Hits@1 Hits@5 Hits@10 MeanRank Hits@1 Hits@5 Hits@10 MeanRank
Tiresias 14.23 33.18 50.61 21.89 19.21 45.29 52.94 17.93
SCNN 12.19 26.31 39.02 37.91 16.82 27.03 40.78 37.06
MDDP 20.95 58.66 79.48 13.53 43.19 68.57 84.12 7.85
TransE 26.61 70.23 83.97 8.01 57.88 79.99 87.27 7.02
TransR 31.33 75.80 87.63 6.89 69.58 84.01 89.01 6.25
PRD 45.11 85.57 91.01 6.11 75.11 88.60 92.85 5.45
Table 4: Rich DDI predictions for Acetylsalicylic acid.
Interacted Drug TransR PRD
Ibritumomab enhance, adverse, toxic, risk, bleeding enhance, toxic, bleeding, platelet, antiplatelet
Alteplase enhance, increase, adverse, toxic, effect enhance, toxic, bleeding, thrombolytic, adverse
Anistreplase enhance, effect, thrombolytic, agents, anticoagulant enhance, anticoagulant, antiplatelet, thrombolytic, agents
Ramipril diminish, antihypertensive, effect, treatment, affect diminish, antihypertensive, inhibitor, doses, affect
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
Tr
ue
 P
os
iti
ve
 R
at
e
False Positive Rate
 PRD
 Tiresias
 TransR
 MDDP
 TransE
 SCNN
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Figure 4: PR curve
We used 10-fold cross-validation on the training set to
tune PRDs embedding model. We determined the optimal
parameters using a grid search strategy. The search ranges
for the various parameters follow: the learning rate λ for the
Adam algorithm {0.1, 0.01, 0.001}, γ for the soft constraints
{0.1, 0.01, 0.001}, the vector dimension k {20, 50, 80, 100},
and all bias constant b1, b2, b3, c were 10 to 10. The training
instances were conducted over 1000 iterations. The running
time per iteration was 391s. The best configurations for
the joint model were: λ = 0.001, γ = 0.01, k = 100,
b1 = 5, b2 = 5, b3 = 1, c = 10, K = 3 and taking L1 as
dissimilarity metric.
We used receiver operator characteristic (ROC) curves
and precision-recall (PR) curves to evaluate the proposed
method on binary DDI-type predictions. For multiple DDI-
type predictions, we followed the setting in TransE [3] and
report the two measures as evaluation metrics: the average
rank of all correct relations (MeanRank) and the proportion
of correct relations ranked in top k (Hits@k). The above
metrics may be biased for methods that rank other correct
labels higher in the same label set. Hence, all other correct
labels were filtered out before ranking. The filtered version
is denoted as “Filter,” and the unfiltered version is denoted
as “Raw.”
4.4 Experiment Results As shown in Figures 3 and 4,
the proposed framework PRD outperformed all baselines.
In terms of the ROC curve, PRD outperformed Tiresias by
6.69%, 7.13% than TransR, around 12% than MDDP and
TransE, while SCNN had the relatively low predictive ability.
According to the PR curve, PRD learned 14.2% better than
Tiresias, which was at the top among three DDI prediction
baselines, 16.8% than TransR, 21.57% than MDDP, 25.33%
than TransE, and 37.89% than SCNN.
Table 3 shows the evaluation results for rich DDI rela-
tion predictions according to the different evaluation metrics
for both the Raw and Filter tests. From these tables, we make
the following observations:
• PRD achieved a significant improvement over all base-
lines. Specifically, PRD outperformed MDDP by
around 10%. MDDP is currently considered to be the
best DDI prediction baseline for multiple DDI type pre-
dictions. Tiresias and SCNN performed poorly because
they neglect various semantic information concerning
DDIs. These results demonstrate the effectiveness of
PRD and its ability to predict rich DDI relations be-
tween drug entities.
• Compared to TransR and TransE, PRD also performed
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better, as it incorporates binary DDI types into the rela-
tion representations learning and also models multiple
DDI labels of a DDI relation simultaneously. This ac-
counts for its promising results in rich DDIs prediction.
4.5 Case Study To further demonstrate PRDs ability on
rich DDI predictions, we select the drug Acetylsalicylic acid
(Aspirin) as a test case. The DDI predictions and rich labels
relations are shown in Table 4. Observe that both TransR
and PRD were able to recommend multiple DDI labels for
the drug interactions and representatives of detailed DDI
information. However, TransR sometimes recommended
similar labels for a specific drug because it is based on a
similarity method. Conversely, PRD was able to recommend
more reasonable labels because it uses a decoder to predict
discriminative DDI information.
Here we also present case study to visualize the ef-
fectiveness of binary DDI types prediction on a DDI net-
work sample. We construct drug-drug networks to indicate
whether any two drugs would result in a binary DDI. A node
in the network denotes a drug. An edge between two nodes
denotes the existence of a DDI. Intuitively, the more drugs
interact, the more risk they will burn. In the network, the
size of the node specifies the degree of risk of a drug. We
classified the degree of risk into various levels using differ-
ent colors, i.e., high-risk is shown as dark green and low-risk
is shown as light green. The red nodes denote forecasting er-
rors of DDI drugs. As shown in Figure 5 to Figure 10, PRD
predicts DDIs mostly accurate. The ID of the drug with high
risk is shown on the node.
5 Conclusions and Future Work
This paper presents a framework for DDI prediction that is
unlike existing models. It can competently predict multi-
labels for a pair of drugs from rich DDIs information in
many ways, ranging from pharmacological mechanisms to
side effects. To the best of our knowledge, this frame-
work is the first to provide a joint translation-based embed-
ding model that learns DDIs by integrating drug knowledge
graphs and biomedical texts simultaneously in a common
low-dimensional space. The model also predicts DDIs using
multi-labels, rather than single or binary labels. Extensive
experiments were conducted on real data sets to demonstrate
the effectiveness and efficiency of the model. The results
show PRD outperforms several state-of-the-art baselines.
In future work, we intend to incorporate a convolutional
neural network to encode the rich DDI text to improve the
performance of the embedding model. Another direction for
our research is to have the embedding model consider the
subgraph features composed in the generated drug knowl-
edge graph during learning. This may make it possible to
predict DDIs among three or more drugs.
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